Clinical-stage biotechnology company Halozyme focuses on developing and commercializing cancer therapies that target the tumor microenvironment (TME). The cornerstone of Halozyme’s technology is ...

SAN DIEGO, CA - Halozyme Therapeutics , Inc. (NASDAQ:HALO), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that board member Connie L. Matsui has decided ...

Throughout the last three months, 9 analysts have evaluated Halozyme Therapeutics HALO, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon.

SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host ...

Helen Torley, president and chief executive officer of Halozyme (HALO). “I am also pleased that we achieved four additional, significant ENHANZE regulatory product and indication approvals in ...

Halozyme Therapeutics (HALO) reported $298.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 29.6%. EPS of $1.26 for the same period compares to ...